Preformulation for tylvalosin tartrate in solid veterinary dosage forms begins with control of the API particle size distribution because the material is often micronized to achieve content uniformity in low-dose blends. Bulk density and tapped density are measured according to Ph. Eur. 2.9.34, powder flow according to Ph. Eur. 2.9.36, and specific surface area by nitrogen adsorption according to Ph. Eur. 2.9.26. A Hausner ratio greater than 1.35 or a Carr index greater than 25 normally indicates that the API requires granulation or automated forced-feeder assistance on the tablet press rather than direct compression. Moisture sorption is recorded at 25 °C/60% RH and 40 °C/75% RH in dynamic vapour sorption equipment; if equilibrium moisture exceeds 2.0% w/w, the API is dried in a vacuum tray dryer at 40 °C and ≤10 kPa until loss on drying is below 1.0% w/w. Binary excipient compatibility studies are conducted in sealed glass vials at 40 °C/75% RH for 4 weeks and evaluated by HPLC-UV. Special attention is given to reducing sugars and alkaline lubricants because the macrolide lactone ring can undergo hydrolytic opening in the presence of free moisture and elevated pH. Published data specific to tylvalosin tartrate in each individual excipient matrix is limited; therefore forced degradation screening is required before final selection. The API should not be stored in unlined aluminium containers under high humidity because tartrate salts can exhibit eutectic moisture uptake at high RH.

Can Wet Granulation Prevent Segregation and Compressibility Failure in Tylvalosin Tablet Blends?

Wet granulation is used when direct compression of tylvalosin tartrate produces unacceptable blend segregation or when the API particle size is too fine for uniform die fill. In a high-shear granulator, the dry blend is mixed at an impeller speed of 150–300 rpm with a chopper speed of 1500–3000 rpm; binder solution, typically povidone K30 at 5–10% w/w in purified water, is added by peristaltic pump at 0.5–2.0 kg/min for production-scale bowls. The endpoint is determined by impeller torque or power consumption because overwetting can generate oversized granules that require additional dry milling and may deaggregate poorly in dissolution testing. The wet mass is passed through a 1.0–2.0 mm screen and dried in a fluid-bed dryer with inlet air temperature 60–70 °C, product temperature 40–45 °C, and final residual moisture 1.5–3.0% w/w. Drying below 1.0% w/w often increases tablet friability and capping at compression forces above 15 kN. The dried granules are milled through a 0.8 mm conical mill, lubricated with 0.5–1.0% w/w magnesium stearate for 2–5 min, and compressed on a rotary tablet press at 30–80 rpm to a hardness of 60–100 N. Over-lubrication produces a hydrophobic film that delays dissolution below the acceptance criteria in Ph. Eur. 2.9.3. Content uniformity is evaluated per Ph. Eur. 2.9.40 with an acceptance value of ≤15; blend uniformity is assessed by stratified sampling and HPLC according to the marketing authorization dossier. Granule particle size distribution is measured by sieve analysis per Ph. Eur. 2.9.38; a typical target is D50 150–250 µm with fines below 75 µm not exceeding 20% w/w because excess fines can cause die fill variation and punch sticking in high-speed compression. Tablet friability is tested per Ph. Eur. 2.9.7 as a release specification, with a limit of ≤1.0% w/w. Moisture-sensitive packaging with aluminium-aluminium blisters or HDPE bottles with desiccant is required if the tablets remain stable only below 60% RH.

Sterile injectable solutions of tylvalosin tartrate are manufactured in an isolator or restricted access barrier system under EU GMP Annex 1 Grade A conditions with Grade B background, and the fill line operates within ISO 14644-1 Class 5. Terminal moist-heat sterilization at 121 °C is generally avoided because the 16-membered macrolide lactone ring is heat-labile and can undergo ester hydrolysis, epoxide formation, and degradation to inactive products; aseptic filtration through a 0.22 µm PVDF or PES filter is the preferred sterilizing operation. Published kinetic data specific to tylvalosin tartrate is limited; forced degradation at 60 °C for 48 h in buffered aqueous media is used to screen hydrolysis products. The solution pH is maintained at 5.0–7.0 with a citrate or acetate buffer; pH below 3.0 accelerates acid-catalyzed hydrolysis of the glycosidic linkages, while pH above 7.5 promotes lactone saponification and reduces antimicrobial activity. Dissolved oxygen is displaced by nitrogen sparging to below 2 ppm and headspace residual oxygen is maintained below 2% v/v; amber Type I glass vials meeting Ph. Eur. 3.2.1 protect the solution from photodegradation. Disodium edetate at 0.01–0.05% w/w may be added as a metal ion chelator because trace iron and copper from stainless steel transfer lines can catalyse oxidative degradation of the macrolide ring. The filled vials are tested for sub-visible particulate matter per Ph. Eur. 2.9.19, sterility per Ph. Eur. 2.6.1, and bacterial endotoxin per Ph. Eur. 2.6.14, with an endotoxin limit derived from the maximum daily dose and the target animal species. Container closure integrity is verified by vacuum decay or high-voltage leak detection per USP <1207>, and the elastomeric closures are a bromobutyl formulation with fluoropolymer coating to minimise extractables reaching the solution. The manufacture of multiple batches on the same line requires cleaning validation data for tylvalosin tartrate residues, with carryover limits established from toxicological risk assessment and verified by HPLC-MS/MS.

Water-Soluble Powder and Granule Blending for Drinking Water Administration

Water-soluble powder formulations are manufactured by low-shear blending of tylvalosin tartrate with dextrose monohydrate, anhydrous citric acid, and sodium chloride to modify dissolution and palatability. The API is screened through 425 µm before blending, then triturated with a 1:5 ratio of dextrose monohydrate and added to a ribbon blender operating at 15–25 rpm for 20–30 min. The finished powder is filled into aluminium-lined sachets with desiccant, and residual moisture is controlled below 2.0% w/w because higher moisture can cause clumping and reduce dissolution uniformity. Dissolution in drinking water is assessed by adding the dose to 1 L of water at 20 °C and 5 °C; the solution must be clear or only slightly opalescent within 5 min under mild agitation. Hard water with total hardness above 200 mg/L CaCO₃ may reduce the visual clarity of the stock solution through calcium-tartrate complexation, so citric acid at 2–5% w/w is incorporated as a pH modifier and chelating aid. The target solution pH is maintained between 4.0 and 6.5 because macrolide derivatives are more stable in slightly acidic media than in neutral or alkaline farm water. Farm stock solutions should be prepared in non-galvanized tanks and consumed within 24 h unless stability data support longer holding; published data for tylvalosin tartrate stability in every regional water composition is limited, so field trials should include assay and pH measurement at 0, 6, 12, and 24 h. Content uniformity of the powder is tested per Ph. Eur. 2.9.40 on single-dose sachets; microbial quality is controlled per Ph. Eur. 5.1.4 with acceptance criteria for oral veterinary products.

When Tylvalosin Premix Is Added to Pelleted Feed, Steam Conditioning Can Reduce Potency

Medicated premix production uses a stepwise diluent blend, typically on a ribbon or paddle mixer, to achieve a coefficient of variation below 5% for the active fraction. The carrier system must be matched to the API density; low-density lignocellulose carriers reduce segregation, while fine mineral carriers such as calcium carbonate can raise the microenvironmental pH and accelerate lactone ring hydrolysis. The premix is sampled at 10 points across the mixer and assayed by HPLC-UV; the acceptance range is 90–110% of label claim. When the premix is incorporated into complete feed and pelleted, steam conditioning at temperatures above 65 °C for more than 30 s can reduce tylvalosin recovery, particularly when moisture exceeds 16% w/w at the conditioner outlet. Published recovery data for tylvalosin tartrate in commercial pellet mills varies with equipment configuration; therefore a process validation protocol should include post-pelleting assay at each conditioning temperature, steam pressure, and production rate. If the mean recovery loss exceeds 10%, the feed must either be manufactured as meal or the premix added after pelleting by post-pelleting liquid application or vacuum coating. Pellet hardness and durability are not proof of chemical stability: loss of antibacterial activity can occur before physical pellet quality changes. Feed mill carryover is controlled by sequencing and flush batches, and cleaning validation in feed manufacturing follows EU Regulation 183/2005 and FDA 21 CFR Part 225. The final medicated feed is tested for homogeneity per the registered method and for microbial quality per the receiving feed mill's HACCP plan.

Capsule filling of tylvalosin tartrate is performed on a dosator or tamping-pin capsule machine under controlled room conditions of 40–60% RH and 15–25 °C. Gelatin capsule shells equilibrated to 13–16% w/w moisture are used; lower shell moisture causes brittleness and splitting, while higher environmental humidity causes the fill powder to adhere to the shell wall and increases fill weight variability. The API-containing blend is prepared with microcrystalline cellulose and pregelatinized starch, and the API is geometrically diluted in 1:1, 1:3, and 1:5 steps before final blending in a bin blender at 20–25 rpm for 30–45 min. Magnesium stearate is added at 0.25–0.75% w/w and mixed for 3–5 min; higher levels or longer mixing reduce dissolution rate by forming a hydrophobic coating on the water-soluble active. In-process fill weight is checked by weighing 20 capsules every 30 min, and the weight variation limit is ±5% for capsules above 300 mg fill weight. Capsule content uniformity is determined per Ph. Eur. 2.9.40, and dissolution is conducted per Ph. Eur. 2.9.3 using apparatus 2 at 50 rpm in 900 mL of purified water or the registered dissolution medium. The filled capsules are packaged in HDPE bottles with desiccant or aluminium-aluminium blisters because moisture ingress above 60% RH can soften the shell and accelerate degradation of the macrolide ring. Automated dust extraction and local containment are required during capsule filling because the micronized API can become airborne and cross-contaminate adjacent lines; direct-reading particle counters verify containment at the operator breathing zone.

Oral solutions of tylvalosin tartrate for direct dosing or pump administration are prepared as aqueous vehicles containing sodium citrate, citric acid, glycerol, and preservatives such as sodium benzoate or potassium sorbate. The API is dissolved in 80% of the final volume of purified water at 20–30 °C under stirring; the pH is adjusted to 5.0–5.5 before adding preservatives because benzoic acid efficacy declines above pH 5.5 and sorbic acid is more effective below pH 6.5. The solution is protected from light and oxygen by using amber PET or glass containers and nitrogen blanketing; dissolved oxygen is kept below 1 ppm where stability data show oxidative degradation. Viscosity is adjusted with glycerol or hydroxyethylcellulose if needed for dosing syringe retention and measured per Ph. Eur. 2.2.10 with a rotational viscometer at 25 °C; a target viscosity of 5–20 mPa·s is common for piston pump dosing. Oral solutions are not necessarily sterile, so microbial quality is controlled per Ph. Eur. 5.1.4. Chemical stability is assessed at 25 °C/60% RH and 40 °C/75% RH per VICH GL2; pH drift of more than 0.5 units over storage indicates buffer failure and requires reformulation. Dosing accuracy in target species is verified with calibrated dosing pumps or syringes; the formulation must remain homogeneous after 24 h in a farm dosing tank.